특발성 폐섬유증(IPF) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Idiopathic Pulmonary Fibrosis (IPF) Emerging Therapy and TPP Insights

Thelansis's "Idiopathic Pulmonary Fibrosis (IPF) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology, characterized by irreversible fibrosis of lung parenchyma and a usual interstitial pneumonia (UIP) pattern on high-resolution CT or histopathology. It primarily affects adults over the age of 60 and is one of the most severe forms of idiopathic interstitial pneumonias.

Clinically, IPF presents with progressive exertional dyspnea and persistent dry cough, along with characteristic "Velcro-like" inspiratory crackles on auscultation. The disease is marked by ongoing epithelial injury, aberrant wound healing, and excessive fibrotic deposition, leading to declining lung function and impaired gas exchange.

IPF follows a relentlessly progressive course, often punctuated by acute exacerbations, and is associated with poor prognosis and reduced survival. While antifibrotic therapies (e.g., pirfenidone and nintedanib) can slow disease progression, they do not reverse fibrosis, and lung transplantation remains the only definitive treatment in eligible patients.

Key Highlights

• IPF is a progressive, high-mortality fibrotic lung disease with limited therapeutic options
• UK diagnosed prevalence expected to increase from ~38.7K to ~49.1K (~2.4% CAGR)

Market Overview

• Germany market projected to grow from ~$210M to ~$415M (~7% CAGR)
• Growth driven by antifibrotic therapies and improved diagnosis, with ongoing unmet need for curative treatments

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• PureTech
• AbbVie
• Mediar Therapeutics
• Tvardi Therapeutics, Incorporated
• Contineum Therapeutics
• Calluna Pharma AS
• Haisco Pharmaceutical Group Co., Ltd.
• Boehringer Ingelheim
• Syndax Pharmaceuticals
• Cumberland Pharmaceuticals
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Bristol-Myers Squibb
• Arrowhead Pharmaceuticals
• Rein Therapeutics
• Regend Therapeutics
• Trevi Therapeutics
• Vicore Pharma AB
• Actelion
• Daewoong Pharmaceutical Co. LTD.
• Overseas Pharmaceuticals, Ltd.
• Pliant Therapeutics, Inc.
• Chiesi Farmaceutici S.p.A.
• Bridge Biotherapeutics, Inc.
• GlaxoSmithKline
• HuniLife Biotechnology, Inc.
• Endeavor Biomedicines, Inc.
• siRNAgen Therapeutics Inc.
• Genosco Inc.
• SPARK Biopharma
• Dragonboat Biopharmaceutical Company Limited
• Mannkind Corporation
• Beijing Tide Pharmaceutical Co., Ltd
• Shanghai Synvida Biotechnology Co.,Ltd.
• Guangdong Raynovent Biotech Co., Ltd
• Avalyn Pharma Inc.
• InSilico Medicine Hong Kong Limited
• MediciNova
• GRI Bio Operations, Inc.
• Nerre Therapeutics Ltd.
• Sunshine Lake Pharma Co., Ltd.
• United Therapeutics
• Melius Pharma AB
• Pulmongene Ltd.
• Agomab Spain S.L.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)